CLL Coverage from Every Angle

Nitin Jain, MD, on Implications of Using Ibrutinib Plus Venetoclax in the Front-Line Setting and Beyond

Posted: Friday, January 10, 2020

Nitin Jain, MD, of The University of Texas MD Anderson Cancer Center, discusses the implications of using ibrutinib plus venetoclax in the front-line treatment of chronic lymphocytic leukemia and how that same treatment is likely to evolve in second-line or later therapies.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.